In addition to buprenorphine monotherapy tablets, film and tablets combining 4 parts buprenorphine and 1 part naloxone (a mu opioid antagonist) are also being used in maintenance treatment for opioid dependence (Chiang and Hawks, 2003). (The original manufacturer of the combination tablets stopped supplying them but generic versions and new brand, Zubsolv®*, are now available.) In fact, the bup...

Background Methadone, a full opioid agonist, and buprenorphine, partial agonist at the receptor, are established first-line medications for maintenance therapy. Transition from methadone to sublingual buprenorphine may precipitate withdrawal is usually performed only in patients on low dose of (<30–40 mg). novel subcutaneous depot (Buvidal) has not been previously described.Objectives To test h...

BACKGROUND Sublingual buprenorphine-naloxone (buprenorphine SL) is a preparation that is used to treat opioid dependence. In addition, the Drug Enforcement Administration (DEA) has acknowledged the legality of an off-label use to treat pain with a sublingual buprenorphine preparation. Buprenorphine SL is unique among the opioid class of analgesics; this compound has a high affinity for the mu-r...

Buprenorphine/naloxone (Suboxone) comprises the partial mu-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4 : 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is pare...

AIM To survey and assess the drug dependence and abuse potential liability of buprenorphine among opiate abusers. METHODS Subjects of opiate dependence with history of buprenorphine use for 3 d at least were surveyed by interview. Physical dependence of buprenorphine was assessed using 30 items opiate withdrawal scale (OWS), which composed of 30 symptoms/signs. A 4-point scale was used to rat...

Background: Acute and chronic pain is prevalent in patients with opioid dependence. Lack of knowledge concerning the complex relationship between pain, opioid use, and withdrawal syndrome can account for the barriers encountered for pain management. This study was designed to evaluate the efficacy of sublingual (SL) buprenorphine for post-operative analgesia, compared with intravenous (IV) morp...

The study aimed to identify the range of buprenorphine doses required to comfortably alleviate symptoms in patients undergoing inpatient heroin withdrawal using a symptom-triggered titration dosing regime, and to identify the patient characteristics that impact upon the buprenorphine dose requirements. The study was conducted in two Australian inpatient withdrawal units, recruiting 63 dependent...

Introduction Buprenorphine is a thebaine derivative that was developed in the 1970s for pain relief. It was approved for substitution therapy in France in 1996, and in the USA in 2002. In Singapore, sublingual buprenorphine (2 and 8 mg tablets) has been available since 2002 for the treatment of opioid addiction, under the brand name Subutex. It is registered as a prescription-only medicine, but...

The aim of this single-dose, randomized, positive control, double-dummy, double-blind, parallel group study was to compare oral bromfenac 10 and 25 mg with sublingual buprenorphine 0.2 and 0.4 mg for treatment of postoperative pain. We studied 91 patients with moderate or severe pain after general surgical or orthopaedic operations, using pain intensity, pain relief, adverse effect, mood and se...

Strong opioids are recommended for treating severe cancer pain in the advanced stages of the disease. Few data are available concerning the efficacy of buprenorphine in cancer pain. We compared transdermal buprenorphine 70 microg/h (BUP TDS) to placebo in an enriched design study. Opioid-tolerant patients with cancer pain requiring strong opioids in the dose range of 90-150 mg/d oral morphine e...